A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62B in HIV-infected Adults With Suppressed Viremia Who Started ART Within 18 Months of a Negative HIV Antibody Test

Trial Profile

A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62B in HIV-infected Adults With Suppressed Viremia Who Started ART Within 18 Months of a Negative HIV Antibody Test

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Aug 2015

At a glance

  • Drugs MVA-HIV62 (Primary) ; PGA2-JS7 (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Adverse reactions
  • Sponsors GeoVax Labs
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Aug 2015 Last checked against ClinicalTrials.gov record.
    • 09 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top